10X Capital Venture Acquisition Corp. III (VCXB)
| Previous close | 10.68 |
| Open | 10.68 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1000 |
| Day's range | 10.68 - 10.74 |
| 52-week range | 9.71 - 11.15 |
| Volume | |
| Avg. volume | 2,374 |
| Market cap | 141.707M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-Q Filing
New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by letter dated November 21, 2023 (the “Notice”), notified 10X III that it was not in compliance with the NYSE American LLC’s (“NYSE American”) continued listing standards because 10X III did not timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Quarterly Report”), whi
- GlobeNewswire
10X Capital Venture Acquisition Corp. III Announces Transfer of Listed Securities to the NYSE American
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) (“10X III”) today announced that it is transferring the listing of its Class A ordinary shares, par value $0.0001 per share (“Class A Ordinary Shares”), redeemable warrants, each exercisable to purchase one Class A Ordinary Share at a price of $11.50 per share (the “Warrants”), and units, each consisting of one Class A Ordinary Share and one-half of one Warrant (the “Units” and
- GlobeNewswire
Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those cells to target and kill HIV instead of being “killed” by the virus. Thirty-eight million people are living with HIV globally, with 1.2 million in the U.S. and 2.3 million in Europe. Although HIV has suitable treatments, those treatments are expensive, lifelong, and can often have side effects.Addimmu
